

● LIVE ON ZOOM

Investor Meeting

Virtual Program Book

DATE

October 29, 2026

TIME

11:00 AM – 12:00 PM ET

6

curated presenting
companies

60

minutes, start to finish

20

minutes in founder
breakout rooms

Agenda

	35 MIN · PITCHES	20 MIN · BREAKOUTS
11:00	11:05	11:40 12:00

11:00
to 11:05 AM

Meeting Opens & Introductions
Skylar Rallison — Community Manager, CONNECTpreneur

11:05
to 11:40 AM

Pitch Sessions
Companies will be introduced by:
Debbie Cline — Founder & Chief of Customer Success, Buzzy Rocket

Cash Margin Partners

Easily

Frenelle PBC

Ginkgo-AI

i-Lumen Scientific

Transverse Medical

11:40
to 12:00 PM

Presenting Company Breakout Rooms
Q&A time with the founders.

IN THIS BOOK

03 Presenting Companies

11 Partners

14 Upcoming Events

04 Executive Summaries

12 Sponsors

10 Speakers

13 Prep Team

Presenting Companies

COMPANY	PRESENTER • FOCUS	RAISE	PG
 Cash Margin Partners	Cash Margin Partners John Valenti • AI-driven inventory liquidation for independent retail	\$550K SAFE	04
	Easily Abhishek Tiwari • Allergy immunotherapy delivered through daily toothpaste	\$2.5 M	05
	Frenelle PBC Jeff Missling • Once-monthly injectable treatment for opioid use disorder	\$3–5 million in preferred stock	06
 Ginkgo-AI	Ginkgo-AI Charles Brown • AI governance for government and regulated enterprises	\$5M seed	07
 i-LUMEN SCIENTIFIC <small>Advancing Vision Restoration</small>	i-Lumen Scientific John VeLure • Restoring vision in macular degeneration	\$28 M	08
	Transverse Medical Eric Goslau • Stroke protection for heart valve replacement procedures	Redeemable Preferred Stock Extension	09

Each company's executive summary follows. Meet the founders in their breakout rooms from 11:40 AM.

CASH MARGIN PARTNERS

Executive Summary | October 26, 2026 | John Valenti, Founder & CEO | Confidential

We turn independent retailers' trapped inventory back into cash.

Think of CMP as StubHub for excess inventory. StubHub turned unused tickets into a liquid market, and John Valenti was there in its early days. CMP matches buyers and sellers of excess inventory across the **\$75B to \$200B** trapped in US independent retail. It is asset light: CMP never takes title, charges no upfront cost and is **paid 20% when the lot settles**.

HOW IT WORKS

Buyers first. A lot with no buyer earns nothing, so CMP sources buyers before it signs sellers: **100+ buyers** and 2 liquidator partners, including a national manifest buyer. Retailers use our free **Rapid Diagnostic Engine** (pricing, bundling, discounting and each SKU's resale value over time), which fills the seller pipeline. The buyer pays and the owner is wired directly. CMP owns all IP.

TRACTION, ABOUT 100 DAYS IN MARKET

- **First paid deal closed in October: \$45K.** The same buyer is already back for a second lot.
- **Largest lot yet, \$2M to \$2.5M, in late-stage negotiation:** \$400K to \$500K to CMP. Buyer and seller identified.
- **Deals in motion:** 44,000-unit intimates lot live (~\$12K to CMP); 173,000-unit hair accessories lot out for signature (~\$10K); a Maryland home-goods chain, our first multi-store seller; ~\$560K of retail lots in the pipeline.
- **4,900+ outbound touches a week** by email, LinkedIn and phone, Delaware through South Carolina.

MARKET, COMPETITION AND DISTRIBUTION

CMP targets owner-operated retailers with \$1M to \$5M in revenue: \$150K to \$400K of dead and slow stock per retailer (CMP diagnostic data) × 1M+ US independents. Inventory software (Shopify Stocky, Cin7, Inventory Planner) stops at the report; liquidators stop at the truck. **CMP does both.** Customers arrive through partners, not paid media: a signed **Xero co-marketing deal** (4.92M paying customers), plus Ramp and Databox. Live from Delaware to South Carolina since July 2026; Florida next, then Georgia and Tennessee; national by end of 2027.

PATH TO PROFITABILITY

About **\$490K in potential 2026 revenue from today's deals alone**. If the largest lot closes, CMP is profitable by year end.

Lot	Status	Projected to CMP
Largest lot to date (\$2M to \$2.5M)	Late-stage negotiation, 20% fee	\$400K to \$500K
Other open lots (intimates, hair accessories, signed lots, follow-on)	Live, out for signature or sourcing buyers	~\$32K
October deal (\$45K)	Closed and paid (one-time 15% rate)	\$7K
Total, today's deals only		~\$490K

Largest lot counted at its \$450K midpoint; other open lots at 50% clearance. Not counted: the Maryland chain, ~\$270K of lots awaiting buyers, ~\$60K cosmetics and all new deals.

TEAM AND BOARD

John Valenti, Founder & CEO (early StubHub; Warner Bros. digital distribution, \$60M in licensing; TCI Interactive). **Ashlr.AI**, platform development. **Henry Fadoni**, Head of Sales. **Ross Blanchard**, Head of Business Development. **Board, both investors:** Kelyn Brannon (took three companies public as CFO; CFO, Celestial AI) and Jeff Freedman (former CAO and General Counsel, CAA). Advisors include Allen Debevoise, Sandy Climan, Prem Akkaraju, Asbed Kassis, Sal Siino and Cindy Zoller.

THE ASK

\$550K additional on a SAFE at a \$5M cap, with a discount. \$450K invested to date, for a \$1M round. Multi-investor close over a 30-day window: \$10K to \$25K angel checks now, \$25K to \$50K checks to close, larger checks in parallel.

John.Valenti@CashMarginPartners.co

Confidential, for prospective investor review. Not an offer to sell or a solicitation to buy securities.

Allergy immunotherapy inside brushing

Make a years-long therapy easier to complete by putting it inside a habit people already keep.



Prescription care built for the bathroom routine

THE CASE

A proven therapy rebuilt around a habit

Shots and drops can modify allergy disease, but they add a separate routine for 3-5 years. Published Year 3 persistence is 6-19% for shots and 5-8% for sublingual treatment.

Easily delivers personalized immunotherapy through toothpaste. Treatment disappears into brushing your teeth instead of adding another daily task.

PROOF OF USE AND COMPLETION

3,000+

protocol patients | 50+ practices | 10 years

80% / 65%

modeled retention | Year 1 active / Year 4 complete

97%

study-day adherence | 48-week Phase 1 study

Company records and model | Published study. Retention and adherence are separate measures.

THE BUSINESS

A narrow share creates a large subscription business

15M modeled U.S. DTC customers represent roughly \$18B annually at \$100 per month.

0.67% of the audience = 100K subscribers

\$10M MRR | \$120M annualized revenue

UNIT ECONOMICS

Gross Margin: **60%**

LTV/CAC Ratio: **8.9X**

Payback Period: **4.2 mos.**

\$100 monthly price | \$250 launch CAC | \$60 monthly gross profit

DEFENSIBILITY

Exclusive consumer rights through 2035

5 issued U.S. patents | 2 families | airborne and seasonal allergies

LAUNCH FOCUS

Families managing airborne allergies first

DELIVERY PARTNERS

Selected care stack

Rowan Care | Beluga Health | Revelation Pharma Intake through refills

CAPITAL PLAN

Fund the \$2.5M launch over 18 months, then scale

MONTH 0
\$500K

Launch

MONTH 6
\$2M

Expand

AFTER REPEATABILITY
UP TO \$25M

Scale

FOUNDING TEAM AND CONTACT



Vikas Patel

Built Rugiet to \$250M+ in revenue.



Abhishek Tiwari

Grew Maxim from \$8M to \$23M in one year.

Investor contact

Abhishek Tiwari

atiwari@easilyhealthcare.com
1-312-799-059

4.8M

People with OUD
in the United States

175K

Patients on long-acting
injectable buprenorphine

\$1.2B

Approximate combined
2025 LAI sales

\$472M

FRN01 Year-5 net revenue
Base-case projection

\$3–5M


Seed-2 preferred equity
\$13M pre-money

COMPANY AND OPPORTUNITY

Frenelle PBC is a Delaware public benefit pharmaceutical company backed by Mayo Clinic Ventures. Its lead product, FRN01, is a preclinical, once-monthly subcutaneous buprenorphine injection designed to expand access to treatment for opioid use disorder (OUD) through a smaller needle, lower cost, and simpler distribution.

An estimated 4.8 million people in the United States have OUD, while approximately 175,000 patients receive long-acting injectable (LAI) buprenorphine. Sublocade and Brixadi generated approximately \$1.2 billion in combined sales in 2025. Frenelle aims to expand this established category by addressing barriers to patient and provider adoption.

TECHNOLOGY AND PRODUCT



FRN01 combines buprenorphine with the Faros™ biodegradable microsphere platform, which has prior clinical experience. FRN01-B has been selected as the lead formulation. Bench release and rat pharmacokinetic (PK) data showed consistent formulation ranking, with a lower initial burst and lower peak exposure for FRN01-B than FRN01-A. Modeling projects that a 170 mg monthly dose can maintain exposure within the therapeutic window. FRN01 human PK and tolerability remain to be demonstrated.

The target profile includes administration through a 30G needle, a projected \$585 monthly wholesale acquisition cost and approximately \$450 monthly net price, and no certified-pharmacy-site Risk Evaluation and Mitigation Strategy (REMS) requirement. The less restrictive distribution profile remains subject to FDA review. A study of 125 qualified OUD prescribers supports interest in the proposed profile; results reflect stated intent rather than realized adoption.

The Faros patent estate includes issued U.S. protection through 2033 and international coverage through 2036, with an additional application seeking protection through 2045. In addition, generic drug approval of a complex long-acting injectable, such as FRN01, is very challenging.

COMMERCIAL STRATEGY AND POTENTIAL LIQUIDITY

Initial market access efforts focus on Medicaid and criminal-justice settings, including office-based opioid treatment providers and federally qualified health centers. The base-case forecast projects \$472 million in Year-5 net revenue and \$953 million in peak annual revenue in 2042. These are modeled outcomes dependent on development success, market share, treatment persistence, and net pricing. Successful Phase 1 results could create a strategic acquisition opportunity; IPO and independent commercialization are additional options.

DEVELOPMENT AND CAPITAL PLAN

Frenelle plans to pursue a 505(b)(2) pathway using a PK bridge to prior FDA findings for buprenorphine. The proposed program includes Phase 1 single/multiple ascending-dose and comparative bioavailability studies, followed by an open-label long-term safety study. Large efficacy studies are not anticipated, subject to FDA agreement. The staged plan budgets approximately \$65 million through approval and pre-launch activities, based on a \$3 million Seed-2. The current timeline places Phase 1 in 2030–31 and approval/commercial launch in 2034.

LEADERSHIP

Jeff Missling, CEO; Lee Techner, CMO; Mark Payne, CFO; Jeff Christensen, Commercial; and Tyler S. Oesterle, MD, MPH, Mayo Clinic addiction-medicine leader. Collective career experience includes more than 10 drug launches, more than 30 clinical trials, 10 biopharma M&A deals, 3 IPOs, and more than \$500 million raised.

SEED-2 FINANCING

Seed-2: \$3–5 million in preferred stock at a \$13 million pre-money valuation

Seed-2 funds manufacturing and formulation (CMC) optimization, minipig PK confirmation, and a pre-investigational new drug (pre-IND) meeting with FDA (Q2'28). The intended milestone is formulation lock for good laboratory practice (GLP) studies and FDA alignment on the IND-enabling plan. Further financing will be required for IND-enabling work and clinical development.

Value Proposition

Company Background: Ginkgo-AI delivers Governed Intelligence powered by Metis™, an AI control plane that governs, enforces and audits artificial intelligence inside the customer's own boundary. Government and regulated enterprises have no centralized way to control AI at scale, and the result is shadow AI, data leakage, unenforceable policy and decisions nobody can reconstruct. Metis sits between the user and the organization's systems and makes every model call, data access and agent action identity-bound, policy-controlled, auditable and reversible — with no data leaving the organizational boundary. It is delivered as an on-premise appliance or as a governed subscription. The company has two signed customers and \$36K of contracted value: the Town of Scottsville is live in production with five workflows in daily use, and Westland Realty Group is in deployment. Ginkgo-AI is raising a \$5M seed, released in three tranches against traction milestones.

Leadership Team:

- Dr. Charles Brown, CEO: Experienced in digital transformation and startups.
- Charles Howard, CTO: Leads AI development.
- Jim Patterson, CFO: Oversees finance, accounting and investments.

The full team numbers nine, with 236+ years of combined experience. The team is supported by a six-member advisory board with experience in state and local municipal operations and management, artificial intelligence, health and human services, federal contracting, education and investment funding.

Technologies/Special Know-How:

Metis is a scalable control plane delivered as an on-premise appliance or a governed subscription, exposing five capabilities: identity, authentication and context management; runtime security and AI guardrails; advanced observability and audit trails; cost governance and resource optimization; and policy enforcement and centralized governance. Those capabilities are composed into vertical solution packs, beginning with Metis Municipal and followed by health and human services and real estate. Revenue comes from three streams: a platform subscription priced by governed node across six tiers (\$10K to \$250K in year one), per-user licenses that expand seat by seat inside the account, and the appliance, purchased outright or taken as hardware-as-a-service. Entry is a \$15K, 90-day paid pilot, prepaid and creditable against the first year.

Market:

State and local government IT spending is a \$160.2B budget line in 2026 — the line Metis sits inside. The initial serviceable market, built bottom-up across Virginia and national state and local accounts, is \$289M. The five-year obtainable market is \$79.9M, or 547 accounts at FY31, representing 28% of the serviceable market.

The opportunity is a measurable gap rather than a forecast: 55.7% of government offices already use AI, while only 42.9% have a written policy governing it. Regulation is closing that gap on the company's behalf — Virginia, Texas, Colorado and the EU all compel the same artifact, which is evidence that AI use was authorized, bounded and auditable. Buyers are not purchasing productivity; they are purchasing the ability to survive an audit.

Distribution Channels:

The motion repeats in three steps. A \$15K, 90-day paid pilot is the wedge, generating revenue on day one and qualifying the buyer. The pilot converts to a production account, which becomes a reference. That reference introduces the next locality, and neighboring jurisdictions buy from each other. Channel amplifies it: Carahsoft on SEWP and GSA for the federal path, 2ndWave and the Virginia Municipal League for municipal reach.

Competition:

A regulated buyer needs five things at once: enforcement inside their own boundary, policy applied at runtime, a complete and replayable audit record, model and vendor neutrality, and workflows written to their statutes. Each competing category delivers some of them. AI governance SaaS is a documentation layer and is cloud-only, so it describes controls rather than enforcing them. Hyperscaler tooling enforces well so a town would have to move its records to the vendor before anything could be governed. AI gateways are developer infrastructure with no audit product and no governance workflow. GovTech incumbents sell systems of record, not a governance plane over them. Metis is positioned as the only offering that covers all five, and it is deliberately neutral with respect to the underlying models and the systems it governs.

\$'000

Financial Projections (Unaudited):

	FY27	FY28	FY29	FY30	FY31
Revenue	3,500	10,100	22,300	39,000	79,900
EBITDA	TBU	TBU	TBU	TBU	TBU

Basis of presentation: annual recurring revenue at exit, constructed account by account at model tier pricing. Hardware, professional services and pilot fees are excluded. FY27 converts the accounts already signed; FY31 reflects 547 accounts, consistent with the serviceable obtainable market above.

Quick Facts

Company Name:

Ginkgo Development Corporation
d/b/a Ginkgo-AI

Contact:

Dr. Charles Brown, CEO

Address:

4210 Electric Road, Suite 1149
Roanoke, VA

Phone: 540.346.3469

Email: info@ginkgo-ai.com

Website: ginkgo-ai.com

Industry: Enterprise Software /
AI Governance

Domain: Government and
Regulated Enterprise

Bank: Bank of Botetourt

Law Firm: Church Legal

Patent Estate: One provisional
patent

Employees: 9 total, 3 full-time

Leadership Team:

- Dr. Charles Brown, CEO
- Charles Howard, CTO
- Jim Patterson, CFO

Amount of Financing Sought:

\$5M seed, three tranches. Post-
money SAFE, \$10M cap.

Current Investors

\$150K founder capital to date.
VIPC programs available.

Use of Funds:

GTM 40%, delivery 35%, product
and cloud 25%

Auditor:

TBU

Restoring vision Not Just Managing Disease

Series B Funding Round:
Seeking \$28.0 M
Convertible Preferred Stock
Share price: US\$1.35
Pre-money: US\$31.6 Million
Post-money: US\$76.9 Million

Age-related Macular Degeneration (AMD) Affects Central Vision

Dry AMD is a chronic disease of the macula (the central retina) that gradually reduces central vision over time. Intermediate AMD is the first stage of the disease to experience vision loss.




1 in 4 people

are affected by AMD and it is the leading cause of blindness in those over age 60.



Clinically Significant, Personally Meaningful

i-Lumen's proprietary dual waveform algorithm generates clinically significant vision improvement supporting a meaningful improvement in quality of life.



61.5%

with ≥ 10 letter improvement in BCVA by month 2

53.8%

maintained ≥ 10 letter improvement in BCVA through month 12

30.8%

with ≥ 15 letter improvement in BCVA at month 3

Restoring the Electrophysiology of the Retina

The i-Lumen AMD System is focused on restoring the electrophysiology of the retina through a novel, non-invasive bioelectric stimulation improving vision for those with intermediate to advanced dry Age-related Macular Degeneration (AMD).

\$850M Strategic Acquisition Benchmark

In late 2025, Alcon completed a benchmark transaction, acquiring another pre-revenue, energy-based, device therapy to treat Dry-AMD for an estimated \$850.0 million.

Clear Line-of-Sight to Strategic - Compelling Potential Return

i-Lumen's clinically meaningful outcomes have generated significant interest from leading ophthalmology companies, including Alcon, Johnson & Johnson, Bausch + Lomb, and Glaukos. The next major inflection point for i-Lumen is the release of primary endpoint data from its i-SIGHT2 Pivotal Study, currently targeted for early 2028. Projecting 10x to 12x return in 30 to 36 months.



EXECUTIVE INVESTMENT SUMMARY

Redeemable Preferred Stock Extension | POINT-GUARD®PRO

Point-GuardProtected® | Safeguard the Brain. Treat the Heart.

MAXIMUM COVERAGE + PROTECTION Across aortic arch and all great vessel inlets	MAXIMUM FILTRATION + DEFLECTION Balanced filtration and controlled deflection	DEVICE NON-INTERFERENCE + EASE-OF-USE Independent pathway; simplicity; predictable workflow
--	---	---

Company & Investment Overview

Transverse Medical, Inc. (TMI) is a Colorado-based medical device company developing POINT-GUARD® PRO, an investigational cerebral embolic protection (CEP) system for transcatheter aortic valve replacement (TAVR). Point-Guard is designed as a femoral-access platform to provide maximum coverage across the aortic arch and all great-vessel inlets, combining filtration and controlled deflection while maintaining an independent pathway intended to minimize interaction with the TAVR procedure.

The Redeemable Preferred Stock Extension provides accredited investors an opportunity to invest at a \$31.78 million pre-money valuation and \$3.50 per share, with an 8.0% cumulative dividend, subject to the definitive offering documents. Capital is intended to advance Point-Guard through design maturity, V&V and preclinical work, staged FDA engagement, additional human evidence, and readiness for the GUARDIAN global clinical program. In parallel, TMI is beginning outreach for a lead investor for a planned Series C financing intended to support the GUARDIAN global clinical program and the next stage of regulatory and commercial development.

Why Transverse Medical. Why Now.

Point-Guard®PRO is advancing through key technical, regulatory, and clinical value inflection points.

CLINICAL + REGULATORY Robust pre-clinical validation and in-human feasibility testing; staged FDA engagement and a defined 510(k)-oriented regulatory strategy with clinically meaningful endpoints.	COMPETITIVE ADVANTAGE Maximum coverage, filtration + deflection; non-interference; stable, predictable deployment; maintained flow + atraumatic retrieval; human + engineering learning.
GLOBAL MARKET OPPORTUNITY Company estimate for 2032: USA 287K devices / \$1.15B revenue; International 221K devices / \$554M; Total 509K devices / \$1.70B.	HEALTH ECONOMICS Company estimates downstream stroke costs at \$9K-\$20K per TAVR case over five years; a 1% absolute reduction may avoid about \$6,550 per case.
UNMET NEED Stroke risk persists after TAVR while cerebral embolic protection remains incomplete and underused. Sentinel directly protects 2 of 3 great-vessel inlets, leaving the left subclavian inlet and left vertebral circulation outside the directly protected field. Estimated CEP utilization is 15%-30%, leaving most TAVR patients without embolic protection. The unmet need is broad cerebral protection across all three great-vessel inlets without disrupting TAVR workflow.	CLINICAL NEED TAVR can generate a debris shower capable of reaching the cerebral circulation and causing overt or silent brain injury. Current project materials cite major stroke of 1.5%-2.9% and overall stroke/TIA of approximately 4%; silent ischemic injury remains substantially more common. The clinical priority is effective brain protection delivered without adding unnecessary device interaction, procedural burden, or procedure time.

Development Discipline & Clinical Learning

Point-Guard 4.0 is being built from human, physician, and engineering learning. The current program applies prior in-human feasibility experience, Bio-Simulation, bench and anatomical simulation, and structured failure-mode testing to improve coverage, deployment consistency, procedural compatibilityand operator usability.

14 Human Evaluations	6 Bio-Simulation Studies	28 Issued Patents	Q4 2026 Target Design Freeze
--------------------------------	------------------------------------	-----------------------------	--

J. Eric Goslau | President & CEO, Co-Founder
970.409.8019 | Eric.Goslau@TransverseMedical.com

Thomas Chilcott | Chief Financial Officer
303.523.0755 | Tom.Chilcott@TransverseMedical.com

ON TODAY'S CALL

Speakers




HOST

Tien Wong

Chairman & CEO,
Opus8, Inc.

Tien Wong is a private investor, serial tech entrepreneur, and capital formation strategist operating at the intersection of VC, private equity, and alternative investments. He is Chairman & CEO of Opus8, Inc., a private investment and advisory firm that invests in exceptional life sciences, medtech, AI, and tech-enabled services companies, and advises promising growth companies and alternative investment fund managers on capital formation, financing strategy, and strategic growth.



MODERATOR • 11:00

Skylar Rallison

Community Manager,
CONNECTpreneur

Skylar is Community Manager for CONNECTpreneur and a Business Analyst at Opus8. A graduate of BYU's Marriott School of Business in Entrepreneurial Management, she brings experience in business management, social media, data analytics, and project management. She fosters engagement across the investor and founder community, and at Opus8 analyzes investment opportunities to help curate high-quality events.



INTRODUCER • 11:05

Debbie Cline

Founder & Chief of Customer Success,
Buzzy Rocket

Debbie is co-founder, chief of customer success at Buzzy Rocket and yellow lab lover. From LA to London, she is well known as an expert in creating that certain elusive magic that drives explosive growth at the intersection of companies and customers. She has proven strategic vision, and isn't afraid to get in the trenches. In fact, she's been doing this at companies big and small for 25+ years. Her background includes executive level positions at both public companies and startups where she has proven over and over again that her passion, drive and results oriented perspective get it done. She is tenacious, loves the game changer and loves to win.

WITH THANKS

Partners



SR NEXT

Fixed-fee legal solutions for startups and emerging growth companies, delivered by senior attorneys. Powered by Shulman Rogers, a full-service firm of nearly 100 attorneys.



Refraction

A nonprofit innovation hub in Northern Virginia. In five years, 300+ member companies have raised over \$350 million.



Dingman Center, University of Maryland

A top-tier entrepreneurship institute taking founders “from the back of a napkin to the first \$1 million in financing.”



FITCI

Frederick Innovative Technology Center: an incubator and accelerator for early-stage science and technology companies, with 52 clients.



Startup Grind

The mid-Maryland chapter of the largest global startup community: 2M+ entrepreneurs in 600+ cities and 130+ countries.



Ryan & Wetmore, P.C.

A proactive accounting and management consulting firm serving the Northeast and Mid-Atlantic since 1988.



Buzzy Rocket

Helps startups grow and scale through marketing, working with only six startups at a time, backed by web developers, designers, and copywriters.



NFP, an Aon company

A leading insurance broker and consultant built on the belief that business is personal.



Keiretsu Forum

A global community of accredited angel, VC, and institutional investors, with 53 chapters on three continents.



MTC Venture Mentoring Services

Free team-based mentoring for Maryland tech and life science CEOs — 75+ ventures enrolled, \$100M raised in capital and grants.



Georgetown Entrepreneurship Initiative

Builds an entrepreneurial mind set and culture across Georgetown and supports the growth of alumni ventures.

WITH THANKS

Sponsors



WITH THANKS

Our Prep Team



MICHAEL HANSON
Consultant
Optimum Dynamics LLC



LAURA HILL
Chief of Staff
Bentley



MARISSA LEVIN
CEO
Successful Culture
International



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

SCAN TO REGISTER

Upcoming Events



NOV 12
**In-Person
Forum**
Baltimore, MD



DEC 10
**In-Person
Forum**
Tysons Corner, VA



JAN 10
**Healthcare
Investor
Brunch**
San Francisco, CA



FEB 4
**In-Person
Forum**
Baltimore, MD

Want to present to our investors?

Apply to pitch at an upcoming virtual meeting or in-person Forum by emailing Skylar Rallison at srallison@opus8.com.

CONNECT with us

CONNECTpreneur.org

